Sign In
Buy PFE
$27.05
+0.290 (+1.08%)
At Close: Aug 10, 2026
Pfizer: Why Being Bullish Makes Sense Despite The Patent Cliff
12:30pm, Friday, 26'th Jun 2026
When Pfizer was coming out of the COVID-induced growth phase in early 2024, I turned bullish alongside CEO Albert Bourla, effectively betting his pension on Pfizer stock. Since then, Pfizer has proven
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
10:01am, Friday, 26'th Jun 2026
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026?
04:55pm, Thursday, 25'th Jun 2026
AbbVie is aggressively expanding its pipeline to offset the impact of biosimilar competition for its top-selling drugs. Pfizer is utilizing substantial capital for acquisitions to diversify its revenu
MRK Gets EU Nod for Keytruda & Padcev Combination in Bladder Cancer
11:06am, Thursday, 25'th Jun 2026
Merck wins EU approval for Keytruda plus Padcev in patients with resectable muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.
Pfizer (PFE) Falls More Steeply Than Broader Market: What Investors Need to Know
06:47pm, Wednesday, 24'th Jun 2026
In the most recent trading session, Pfizer (PFE) closed at $24.04, indicating a -2.75% shift from the previous trading day.
Pfizer Declares Third-Quarter 2026 Dividend
03:52pm, Wednesday, 24'th Jun 2026
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 third-quarter 2026 dividend on the company's common stock, payable September 1, 2026, to
FDA Approves Pfizer's IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance
03:00pm, Wednesday, 24'th Jun 2026
Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) approved IBRANCEÂ (palbociclib) in combination with trastuzumab, with or w
FDA Approves Pfizer's IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance
02:10pm, Wednesday, 24'th Jun 2026
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) approved IBRANCE® (palbociclib) in combination with trastuzumab, with or without pertuzu
Nike names former Pfizer CFO David Denton as finance chief
10:57am, Wednesday, 24'th Jun 2026
Nike Inc (NYSE:NKE, XETRA:NKE) has announced that David Denton will join the company as executive vice president and chief financial officer effective August 17, succeeding Matthew Friend, who will re
Pfizer dismissed from US states' drug price-fixing lawsuit
10:51am, Wednesday, 24'th Jun 2026
Pfizer has been dismissed as a defendant in a sweeping antitrust lawsuit in which most U.S. states accused dozens of drugmakers and executives of fixing generic drug prices.
LLY or PFE: Which Drugmaker Offers the Stronger Growth Story?
10:00am, Wednesday, 24'th Jun 2026
Lilly's GLP-1 leadership, expanding pipeline and strong earnings growth outlook make it a standout pick over Pfizer despite its premium valuation.
Pfizer Stock Trades Flat Following Mixed Phase 3 Lung Cancer Trial Data
09:20am, Wednesday, 24'th Jun 2026
Pfizer Inc. (NYSE:PFE) shares are trading flat during Wednesday's premarket session as traders weigh mixed Phase 3 trial headlines alongside a firmer overnight tape. Here's what investors need to know
Nike's New CFO Isn't a Retail Insider—He's Coming From Pfizer
08:09am, Wednesday, 24'th Jun 2026
Nike names David Denton, a former Pfizer and CVS Health executive, as its next chief financial officer, and provides updated guidance.
Biotech's Silent Resurgence (5-Year Base Breakout)
05:21pm, Tuesday, 23'rd Jun 2026
The biotech sector's fundamentals are shifting rapidly-and the smartest money on Wall Street is already quietly rotating into the sector.
2 High-Yield Dividend Stocks to Buy and Hold for a Decade
04:30pm, Tuesday, 23'rd Jun 2026
These healthcare leaders have encountered challenges in recent years. However, they are slowly improving their businesses, partly through innovation.
